NEO — NeoGenomics Inc
NASDAQ · Healthcare · Diagnostics & Research
$17.79
+$0.34 (+1.95%)
NeoGenomics Inc (NEO) is a diagnostics & research company listed on NASDAQ. It is led by Anthony P. Zook, based in 9490 NeoGenomics Way, Fort Myers, FL, United States, 33912, with about 2,200 employees. NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through two segments: Clinical Services and Advanced Diagnostics. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company offers molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.
Net income was -$27.1M. NEO currently screens at market cap $924.0M.
Use this NEO page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the NEO quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the NEO SEC filings page. Lician reads the product cache first so this HTML stays unique to NeoGenomics Inc even when a live quote feed is slow.
About NeoGenomics Inc
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through two segments: Clinical Services and Advanced Diagnostics. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company offers molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.
NEO Key Statistics
Market Cap
$924.03M
Volume
872,049
Previous Close
$16.41
Day Range
$16.37 – $16.90
EPS
$0.00
Revenue
$0.00
Net Income
-$78.73M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
2,200
NEO Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$78.73M | -$87.97M | -$144.25M | -$8.35M |
| EPS (Diluted) | $0.00 | $0.00 | $0.00 | $0.00 |
Total Assets
$1.64B
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$367.01M
Operating Cash Flow
$7.02M
Free Cash Flow
$0.00
NeoGenomics Inc Company Information
- CEO & Director
- Anthony P. Zook
- Headquarters
- 9490 NeoGenomics Way, Fort Myers, FL, United States, 33912
- Website
- www.neogenomics.com
- Phone
- 239 768 0600
- IPO / Founded
- 1999-11-02
- Sector
- Healthcare
- Industry
- Diagnostics & Research